VVOS Stock Overview
A medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vivos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.96 |
| 52 Week High | US$48.79 |
| 52 Week Low | US$1.91 |
| Beta | 7.71 |
| 11 Month Change | 40.93% |
| 3 Month Change | 26.50% |
| 1 Year Change | -51.87% |
| 33 Year Change | -97.55% |
| 5 Year Change | n/a |
| Change since IPO | -98.68% |
Recent News & Updates
Recent updates
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story
Sep 10
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Apr 25It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Feb 02Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Apr 18Vivos Therapeutics again delays Q2 2022 results
Aug 23Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada
Jun 29Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be
May 21Vivos Therapeutics: First Take After The Broad Market Sell-Off
Mar 06Vivos Therapeutics: Reimagining Sleep
Jul 30Vivos Therapeutics prices $24M follow-on offering
May 07Shareholder Returns
| VVOS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 13.6% | -1.4% | -3.4% |
| 1Y | -51.9% | 14.9% | 19.6% |
Return vs Industry: VVOS underperformed the US Healthcare industry which returned 14.9% over the past year.
Return vs Market: VVOS underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| VVOS volatility | |
|---|---|
| VVOS Average Weekly Movement | 13.7% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VVOS's share price has been volatile over the past 3 months.
Volatility Over Time: VVOS's weekly volatility has decreased from 120% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 119 | R. Huntsman | www.vivos.com |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.
Vivos Therapeutics, Inc. Fundamentals Summary
| VVOS fundamental statistics | |
|---|---|
| Market cap | US$10.07m |
| Earnings (TTM) | -US$12.04m |
| Revenue (TTM) | US$14.02m |
0.7x
P/S Ratio-0.8x
P/E RatioIs VVOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVOS income statement (TTM) | |
|---|---|
| Revenue | US$14.02m |
| Cost of Revenue | US$5.60m |
| Gross Profit | US$8.42m |
| Other Expenses | US$20.47m |
| Earnings | -US$12.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.54 |
| Gross Margin | 60.07% |
| Net Profit Margin | -85.90% |
| Debt/Equity Ratio | 0% |
How did VVOS perform over the long term?
See historical performance and comparison